請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33199完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 黃麗華(Lih-Hwa Hwang) | |
| dc.contributor.author | Tsai-Yi Lu | en |
| dc.contributor.author | 呂采宜 | zh_TW |
| dc.date.accessioned | 2021-06-13T04:28:56Z | - |
| dc.date.available | 2006-09-01 | |
| dc.date.copyright | 2006-08-03 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-07-20 | |
| dc.identifier.citation | Bode, J. G., Ludwig, S., Ehrhardt, C., Albrecht, U., Erhardt, A., Schaper, F., Heinrich, P. C., and Haussinger, D. (2003). IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. Faseb J 17, 488-490.
Bukh, J., Purcell, R. H., and Miller, R. H. (1994). Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A 91, 8239-8243. Cai, Z., Zhang, C., Chang, K. S., Jiang, J., Ahn, B. C., Wakita, T., Liang, T. J., and Luo, G. (2005). Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 79, 13963-13973. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362. Dansako, H., Naganuma, A., Nakamura, T., Ikeda, F., Nozaki, A., and Kato, N. (2003). Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res 97, 17-30. Duong, F. H., Christen, V., Berke, J. M., Penna, S. H., Moradpour, D., and Heim, M. H. (2005). Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J Virol 79, 15342-15350. Duong, F. H., Filipowicz, M., Tripodi, M., La Monica, N., and Heim, M. H. (2004). Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126, 263-277. Egger, D., Wolk, B., Gosert, R., Bianchi, L., Blum, H. E., Moradpour, D., and Bienz, K. (2002). Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76, 5974-5984. Einav, S., Elazar, M., Danieli, T., and Glenn, J. S. (2004). A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. J Virol 78, 11288-11295. Elazar, M., Liu, P., Rice, C. M., and Glenn, J. S. (2004). An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol 78, 11393-11400. Feld, J. J., and Hoofnagle, J. H. (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967-972. Florese, R. H., Nagano-Fujii, M., Iwanaga, Y., Hidajat, R., and Hotta, H. (2002). Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res 90, 119-131. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975-982. Gale, M. J., Jr., Korth, M. J., Tang, N. M., Tan, S. L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R., and Katze, M. G. (1997). Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217-227. Gao, B., Hong, F., and Radaeva, S. (2004). Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 39, 880-890. Geiss, G. K., Carter, V. S., He, Y., Kwieciszewski, B. K., Holzman, T., Korth, M. J., Lazaro, C. A., Fausto, N., Bumgarner, R. E., and Katze, M. G. (2003). Gene expression profiling of the cellular transcriptional network regulated by alpha/beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J Virol 77, 6367-6375. Gosert, R., Egger, D., Lohmann, V., Bartenschlager, R., Blum, H. E., Bienz, K., and Moradpour, D. (2003). Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 77, 5487-5492. Guo, J., Hui, D. J., Merrick, W. C., and Sen, G. C. (2000). A new pathway of translational regulation mediated by eukaryotic initiation factor 3. Embo J 19, 6891-6899. Gutterman, J. U. (1994). Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 91, 1198-1205. Heim, M. H., Moradpour, D., and Blum, H. E. (1999). Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 73, 8469-8475. Ishido, S., Fujita, T., and Hotta, H. (1998). Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus. Biochem Biophys Res Commun 244, 35-40. Jayan, G. C., and Casey, J. L. (2002). Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2. J Virol 76, 3819-3827. Kanda, T., Basu, A., Steele, R., Wakita, T., Ryerse, J. S., Ray, R., and Ray, R. B. (2006). Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol 80, 4633-4639. Kato, J., Kato, N., Yoshida, H., Ono-Nita, S. K., Shiratori, Y., and Omata, M. (2002). Hepatitis C virus NS4A and NS4B proteins suppress translation in vivo. J Med Virol 66, 187-199. Katze, M. G., He, Y., and Gale, M., Jr. (2002). Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2, 675-687. Kessler, D. S., Levy, D. E., and Darnell, J. E., Jr. (1988). Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes. Proc Natl Acad Sci U S A 85, 8521-8525. Koretz, R. L., Abbey, H., Coleman, E., and Gitnick, G. (1993). Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 119, 110-115. Lechward, K., Awotunde, O. S., Swiatek, W., and Muszynska, G. (2001). Protein phosphatase 2A: variety of forms and diversity of functions. Acta Biochim Pol 48, 921-933. Lindenbach, B. D., Evans, M. J., Syder, A. J., Wolk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., and Rice, C. M. (2005). Complete replication of hepatitis C virus in cell culture. Science 309, 623-626. Liu, B., Liao, J., Rao, X., Kushner, S. A., Chung, C. D., Chang, D. D., and Shuai, K. (1998). Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 95, 10626-10631. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M., and Albrecht, J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965. McLauchlan, J. (2000). Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 7, 2-14. Melen, K., Fagerlund, R., Nyqvist, M., Keskinen, P., and Julkunen, I. (2004). Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J Med Virol 73, 536-547. Miller, K., McArdle, S., Gale, M. J., Jr., Geller, D. A., Tenoever, B., Hiscott, J., Gretch, D. R., and Polyak, S. J. (2004). Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res 24, 391-402. Mowen, K. A., Tang, J., Zhu, W., Schurter, B. T., Shuai, K., Herschman, H. R., and David, M. (2001). Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 104, 731-741. Naganuma, A., Nozaki, A., Tanaka, T., Sugiyama, K., Takagi, H., Mori, M., Shimotohno, K., and Kato, N. (2000). Activation of the interferon-inducible 2'-5'-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol 74, 8744-8750. Nakade, K., Handa, H., and Nagata, K. (1997). Promoter structure of the MxA gene that confers resistance to influenza virus. FEBS Lett 418, 315-318. Park, J. S., Yang, J. M., and Min, M. K. (2000). Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem Biophys Res Commun 267, 581-587. Pavlovic, J., Zurcher, T., Haller, O., and Staeheli, P. (1990). Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 64, 3370-3375. Pawlotsky, J. M. (2003). Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 59, 1-11. Pawlotsky, J. M. (2004). Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 12, 96-102. Polyak, S. J., Khabar, K. S., Paschal, D. M., Ezelle, H. J., Duverlie, G., Barber, G. N., Levy, D. E., Mukaida, N., and Gretch, D. R. (2001). Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 75, 6095-6106. Ritchie, K. J., Hahn, C. S., Kim, K. I., Yan, M., Rosario, D., Li, L., de la Torre, J. C., and Zhang, D. E. (2004). Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med 10, 1374-1378. Samuel, C. E. (2001). Antiviral actions of interferons. Clin Microbiol Rev 14, 778-809. Schonthal, A. H. (1998). Role of PP2A in intracellular signal transduction pathways. Front Biosci 3, D1262-1273. Takeda, K., and Akira, S. (2000). STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11, 199-207. Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N., and Lai, M. M. (1999). Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107-110. ten Hoeve, J., de Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M., and Shuai, K. (2002). Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22, 5662-5668. Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H. G., Mizokami, M., et al. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11, 791-796. Wu, T. R., Hong, Y. K., Wang, X. D., Ling, M. Y., Dragoi, A. M., Chung, A. S., Campbell, A. G., Han, Z. Y., Feng, G. S., and Chin, Y. E. (2002). SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J Biol Chem 277, 47572-47580. Yanagi, M., St Claire, M., Emerson, S. U., Purcell, R. H., and Bukh, J. (1999). In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci U S A 96, 2291-2295. Yeh, T. C., and Pellegrini, S. (1999). The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci 55, 1523-1534. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33199 | - |
| dc.description.abstract | C型肝炎病毒（HCV）的感染已經成為公共衛生以及傳染病學界的重要課題之一。根據世界衛生組織的統計，全世界約有百分之三的人為HCV的帶原者，其中高達百分之八十的人在二十到三十年之後會發生肝硬化，甚至最後死於HCV所引起的肝癌。目前僅有長效型的甲型干擾素（IFN-α）合併抗病毒藥物Ribavirin可治療HCV的感染，但是成效最多只有百分之五十至六十，而且隨著病毒基因型的不同也會有所差異。本研究主要從兩方面來探討造成HCV無法被IFN-α清除的分子機制。首先，我們確認HCV的NS3/4A、NS4B和NS5A蛋白質具有抑制IFN-α對下游JAK-STAT signaling活化的能力。在檢驗每個活化過程的步驟之後，發現NS4B可以阻止ISGF3 complex和DNA的結合，因而導致ISRE主導的基因轉錄無法被啟動。另一方面，我們也重新檢視core在ISRE活化過程當中的影響。在七個從病人血清裡分離出來、分屬基因型1b和2a的core clone當中，每個clone對於ISRE的活化和下游ISG的表現都有不同程度的影響。於是我們比對這七個core的胺基酸序列，並推測某些胺基酸的改變是造成此現象的原因。根據以上的結果，我們認為更多關於NS4B對抗IFN-α訊息傳遞所使用機制的研究，將有助於開發對抗HCV感染的新方法；同時我們也要指出，研究core胺基酸序列的改變與其如何影響JAK-STAT signaling的關係，將有助於釐清core在HCV對抗IFN-α時所扮演的角色。 | zh_TW |
| dc.description.abstract | Hepatitis C virus (HCV) infection is one of the major problems of public health worldwide. Approximate 3% of the world’s population are chronically infected and may gradually develop chronic hepatitis, liver cirrhosis, or hepatocellular carcinoma (HCC) in the subsequent 20 to 30 years. IFN-alpha is one of the cytokines produced by most animal cells to resist viral replication and is by far the most standard therapy for HCV infection. However, the overall achievement of eliminating HCV only reaches 50-60% and is significantly altered by the virus genotypes. Here we investigated the underlying mechanisms from two aspects. First, we investigate the mechanisms that NS3/4A, NS4B, or NS5A used to inhibit the IFN-alpha-induced responses. The signaling of ISRE activation was examined step by step. It was found that NS4B significantly reduced the DNA binding ability of ISGF3. Second, we examined the effects of core on the ISRE activity using seven clones derived from patient sera infected by HCV genotype 1b or 2a. Distinct properties on ISRE activity and expression of ISGs were demonstrated clone by clone, and some putative amino acid changes were proposed to be responsible for these obscure results. We thus suggested that HCV NS4B deserved more attention for the development of new anti-HCV strategies and when attempting on unraveling the character of core, one should beware of the influence caused by every single amino acid substitutions. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T04:28:56Z (GMT). No. of bitstreams: 1 ntu-95-R93445109-1.pdf: 2089760 bytes, checksum: 4ccbe0648cb738197b82614dc884df4c (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | CHAPTER 1 INTRODUCTION 1
1.1 Hepatitis C Virus 2 1.1.1 HCV infection as a world health problem 2 1.1.2 Genome structure and protein characteristics of HCV 2 1.1.3 HCV epidemiology in Taiwan 4 1.1.4 Current strategy in preventing and curing of HCV infection 5 1.2 Eukaryotic Interferon-α (IFN-α) Responses 6 1.2.1 Role of IFN-α in innate immunity 6 1.2.2 IFN-α-mediated JAK-STAT pathway 6 1.2.3 Negative regulation of JAK-STAT pathway 8 1.2.4 HCV against IFN-α action 9 1.3 Rationales and Aims of the Present Study 10 1.3.1 Mechanistic studies of the effects of HCV proteins on the IFN-α signaling 10 1.3.2 Influences of HCV core proteins from different genotypes on the IFN-α signaling 10 CHAPTER 2 MATERIALS AND METHODS 12 2.1 Source of IFN-α Used in this Study 13 2.2 Antibodies 13 2.3 Cell Lines, Cell Culture, Transfection and Transduction 14 2.4 Primers Used in this Study 15 2.5 Isolation of HCV cDNA from Patient Serum and the Cloning of Core 16 2.6 Total Cell Lysate Preparation and Western Blots 17 2.7 Co-immunoprecipitation (Co-IP) 19 2.8 Immunofluorescence Assay (IFA) 19 2.9 Compartmentalization of Cytoplasmic and Nuclear Proteins 20 2.10 Immunoprecipitation of Arginine-methylated STAT1 21 2.11 Chromatin Immunoprecipitation (ChIP) 21 2.12 Dual-luciferase Assay (DLA) 23 2.13 Quantitative Real-time RT-PCR 24 CHAPTER 3 RESULTS 26 3.1 Mechanistic Studies of the Effects of HCV Proteins on the IFN-α Signaling 27 3.1.1 Identification of potential HCV proteins that can suppress IFN-α responses 27 3.1.2 Selection of the gene deliver system 27 3.1.3 Expression and activation of each component of ISGF3 complex under IFN-α stimulation 29 3.1.4 Formation of STAT1-STAT2 heterodimer after IFN-α treatment 30 3.1.5 IFN-α-induced nuclear translocation of STAT1 32 3.1.6 The possible role of PP2Ac in the anti-IFN-α effects of HCV proteins 33 3.1.7 Assessment of IFN-α-mediated transcriptional activation by ChIP 35 3.2 Influences of HCV Core Proteins from Different Genotypes on the IFN-α Signaling 36 3.2.1 ISRE-driven luciferase activity in 293T cells 36 3.2.2 The transcriptional activation of ISG15, ISG56, MxA and ADAR 37 3.2.3 The amount of IL-8 mRNA in core-transfected 293T cells 38 3.2.4 Comparison of sequences between HCV core clones 38 CHAPTER 4 DISCUSSION 40 4.1 Summary of the Findings in Studying the Antagonistic Effects of HCV NS3/4A, NS4B, and NS5A on IFN-α Signaling 41 4.2 Suggested Function of NS4B in Eukaryotic Cells 42 4.3 The Anti-IFN-α Activities of NS3/4A and NS5A 43 4.4 The Divergent Property of HCV Core Protein 44 4.5 Mechanisms Proposed by Other Groups 45 4.5.1 In polyprotein expression system 45 4.5.2 In single protein expression system 46 4.6 Concluding Remarks 46 FIGURES AND TABLES 48 REFERENCES 68 | |
| dc.language.iso | en | |
| dc.subject | 甲型干擾素 | zh_TW |
| dc.subject | Ｃ型肝炎病毒 | zh_TW |
| dc.subject | JAK | en |
| dc.subject | HCV | en |
| dc.subject | ISRE | en |
| dc.subject | STAT | en |
| dc.subject | IFN-alpha | en |
| dc.title | Ｃ型肝炎病毒蛋白對細胞內甲型干擾素反應可能之影響 | zh_TW |
| dc.title | The Possible Effects of HCV Proteins on Cellular IFN-alpha Responses | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 李建國(Chien-Kuo Lee),林宜玲(Yi-Ling Lin),陳美如(Mei-Ru Chen) | |
| dc.subject.keyword | Ｃ型肝炎病毒,甲型干擾素, | zh_TW |
| dc.subject.keyword | HCV,IFN-alpha,JAK,STAT,ISRE, | en |
| dc.relation.page | 75 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-07-21 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 未授權公開取用 | 2.04 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。